We have sent a letter to Senate Health, Education, Labor and Pensions (HELP) Committee leadership that highlights the implications of the Verifying Accurate Leading-edge IVCT Development (VALID) Act. Because the bill would modify the regulatory framework for laboratory developed tests, the VALID Act could have serious unintended consequences for children’s health and children’s hospitals. We are asking the committee to address those concerns before advancing the Senate FDA user fee package legislation that includes the VALID Act.
VALID Act Letter
Related Content
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
CHA Responds to 340B Draft Bill and Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Response to Cell and Gene Therapy RFI
Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.